Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked condition caused by a deficiency of functional dystrophin protein. Patients experience progressive muscle weakness, cardiomyopathy and have a decreased life expectancy. Standards of care, including treatment with steroids, and multidisciplinary approa...
Saved in:
Main Authors: | Theodora Markati (Author), Liesbeth De Waele (Author), Urlike Schara-Schmidt (Author), Laurent Servais (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
by: Fatima Amor, et al.
Published: (2021) -
Gene therapy for spinal muscular atrophy: timing is key
by: Laurent Servais
Published: (2024) -
Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (1989) -
Early Development in Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (1990) -
Theragnosis for Duchenne Muscular Dystrophy
by: Leonela Luce, et al.
Published: (2021)